TNFRSF4 and neoplasm: To promote OX‐40 stimulatory signaling, Dong lab screened a library of phospholipid nanoparticles to optimize the delivery efficacy of OX‐40 mRNA in vitro and in vivo, thereby increasing OX‐40 receptor expression levels on T cells in TME.[88] This T cell targeting strategy significantly enhanced therapeutic effect of anti‐OX‐40 antibodies in A20 and B16F10 tumor models, particularly in combined treatments with anti‐CTLA‐4 and anti‐PD‐1 mAbs.